ReviewJMA journal2025
Serum Uric Acid as a Potential Risk Marker for Atherosclerotic Cardiovascular Disease in Japanese Adults: Using the Hisayama Study-based Prediction Model.
Review in JMA journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The correlation between serum calcium and asprosin in elderly patients with type 2 diabetes mellitus in community.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Atherosclerotic cardiovascular disease (ASCVD) risk profiles vary among populations. In Japan, a prediction model for the 10-year estimate of ASCVD risk, integrating coronary artery disease and atherothrombotic cerebral infarct risk assessments, has been developed based on the Hisayama Study. While hyperuricemia can promote atherosclerosis, serum uric acid levels are not included as a risk factor in the 10-year ASCVD prediction model. Methods: We investigated the association between serum uric acid levels and 10-year ASCVD risk in 5,984 Japanese adults (3,285 males, 2,699 females) aged 40-79 years who underwent health check-ups between 2020 and 2022. The 10-year ASCVD risk scores were calculated using the aforementioned prediction model. Results: Participants in the lowest quartile of serum uric acid levels (3.8 ± 0.6 mg/dL) had a mean 10-year ASCVD risk of 2.1 ± 3.2%, while those in the highest quartile (7.2 ± 0.7 mg/dL) had a mean risk of 4.3 ± 4.6% (p < 0.001). A significant positive correlation was observed between serum uric acid levels and 10-year ASCVD risk scores (r = 0.34, p < 0.001). Multiple linear regression analysis also revealed that serum uric acid levels remained an independent predictor of 10-year ASCVD risk after adjusting for other risk factors (β = 0.02, p < 0.001). Conclusions: This study indicates that serum uric acid levels may serve as a useful marker for ASCVD risk assessment, particularly in the Japanese population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.